Takeda Submits Application For Fixed-Dose Blopress And Diuretic Combination In Japan
This article was originally published in PharmAsia News
Takeda Pharmaceutical submitted a new drug application for a fixed-dose combination tablet of Blopress (candesartan cilexetil) and diuretic (hydrochlorothiazide) for treatment of hypertension to Japan's Ministry of Health, Labor and Welfare. Launched in 1999, Blopress is an angiotensin II receptor blocker and has become the first ARB indicated for chronic heart failure in Japan. Hydrochlorothiazide is classified as a thiazide diuretic and lowers blood pressure by increasing the flow of urine. Takeda's Development Division General Manager Masaomi Miyamoto said the application will maximize the value of Blopress. Currently, Takeda has fixed-dose combinations of Actos with sulfonylurea, and Actos with biganide, which are being marketed overseas. (Click here for more - Japanese language
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.